We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

21 hedge funds and large institutions have $4.51M invested in Biolase, Inc. in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

11% more funds holding

Funds holding: 19 → 21 (+2)

31% less capital invested

Capital invested by funds: $6.54M → $4.51M (-$2.03M)

Holders
21
Holders Change
+2
Holders Change %
+10.53%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$37.3K
2
Renaissance Technologies
Renaissance Technologies
New York
+$24.9K
3
WVP
Worth Venture Partners
New Jersey
+$24.9K
4
DAS
Dynamic Advisor Solutions
Arizona
+$10.9K
5
CFGS
Concourse Financial Group Securities
Alabama
+$9.32K

Top Sellers

Rank Fund Capital Flow
1
TMC
Trellus Management Company
Florida
-$9K
2
Morgan Stanley
Morgan Stanley
New York
-$1.55K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$1.55K

BIOL Hedge Fund Activity: Q1 2020 in Review

21 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2020, worth a combined $4.51M — down 31% from $6.54M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BIOL positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $37.3K. The largest seller was Trellus Management Company, exiting entirely with an estimated $9K sold.

  • 21 institutional investors held Biolase, Inc. (BIOL) as of Q1 2020, up from 19 in Q4 2019.
  • Funds reported $4.51M of Biolase, Inc. stock for Q1 2020, down 31% quarter-over-quarter.
  • 4 funds opened new Biolase, Inc. positions in Q1 2020 and 1 closed out, a net change of +3 holders.
  • The largest Biolase, Inc. buyer in Q1 2020 was Perkins Capital Management, an estimated $37.3K added.
  • The largest Biolase, Inc. seller in Q1 2020 was Trellus Management Company, an estimated $9K sold.

Based on aggregated 13F filings for Q1 2020.